Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dear Visitor: Equitymaster will be under maintenance from 10:00AM to 11.30AM on Sunday, 25 March 2018. During this period, our websites will be accessible though there is a possibility of some intermittent accessibility issues. Please bear with us. We are taking yet another step to make browsing Equitymaster a much faster experience! Thank you.

Auto drives down markets
Mon, 16 May 11:30 am

Indian stock markets continued to sink deeper in the red on sell off in heavy weights over the last two hours of trade. Stocks from the auto and metals space are trading weak while stocks from the healthcare space are trading firm.

The BSE-Sensex is down by 153 points while NSE-Nifty is trading 37 points below the dotted line. BSE Midcap index is down by 0.5% while BSE Small cap index is trading 0.3% below Monday's closing. The rupee is trading at 45.05 to the US dollar.

Pharma stocks are trading firm led by Glenmark Pharma and Wockhardt. As per a press release by Glenmark Pharma, its wholly owned subsidy Glenmark Pharmaceuticals SA has entered into a license agreement with global pharma major Sanofi for development and commercialization of GBR500. GBR 500 is a monoclonal antibody to treat Crohn's disease as well as other chronic autoimmune disorders.

As per the agreement, Glenmark will receive an upfront payment of US$ 50 m from Sanofi. This payment includes US$ 25 m on closing of the deal and the remaining US$ 25 m on assessment by Sanofi of certain data to be provided by Glenmark. In addition to the payment, Glenmark could potentially receive payment for success-based development and regulatory and commercial milestones. As per the agreement, Sanofi will have the exclusive marketing rights for North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay. In addition, the company will have co-marketing rights in Brazil, Russia, Australia and New Zealand. Glenmark would receive double-digit royalties on sales of products under this license. For India and rest of the world, Glenmark will have exclusive marketing rights.

Hotel stocks are trading mixed with Oriental Hotels and Country Club trading firm while Indian Hotel and Hotel Leelaventure are trading weak. As per the Chairperson and CEO of EIH Limited, Mr P.R.S Oberoi, 60% of the company's business in 10 years time will come from management contracts. This is as the company is shifting its focus away from owning real estate. However, the company will develop the land it already owns. EIH which owns around 30 properties under the Oberoi and Trident brands has recently began to take up hotels on management contract. In this business model, hotel companies operate their brands in properties owned by someone else for a fee. EIH is currently charging a management contract fee of 12-16% of net profits. EIH operates in the five star (Trident) and luxury (Oberoi) segments and plans to continue to operate in these segments only.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Auto drives down markets". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 23, 2018 (Close)